INVESTIGATIONAL PRODUCT for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 12 adverse event reports in the FDA FAERS database where INVESTIGATIONAL PRODUCT was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for INVESTIGATIONAL PRODUCT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Febrile neutropenia | 241 | 4.5% | 29 | 215 |
| Pneumonia | 229 | 4.3% | 69 | 209 |
| Acute kidney injury | 198 | 3.7% | 35 | 185 |
| Pyrexia | 189 | 3.5% | 17 | 171 |
| Anaemia | 176 | 3.3% | 21 | 151 |
| Diarrhoea | 170 | 3.2% | 28 | 131 |
| Sepsis | 168 | 3.1% | 66 | 147 |
| Dyspnoea | 156 | 2.9% | 26 | 124 |
| Nausea | 134 | 2.5% | 14 | 93 |
| Hypotension | 130 | 2.4% | 22 | 116 |
| Vomiting | 128 | 2.4% | 15 | 99 |
| Neutropenia | 126 | 2.3% | 16 | 68 |
| Dehydration | 113 | 2.1% | 8 | 103 |
| Fatigue | 111 | 2.1% | 18 | 77 |
| Death | 102 | 1.9% | 102 | 33 |
Other Indications for INVESTIGATIONAL PRODUCT
Non-small cell lung cancer (288)
Acute myeloid leukaemia (210)
Product used for unknown indication (197)
Malignant melanoma (181)
Breast cancer (168)
Plasma cell myeloma (151)
Chronic lymphocytic leukaemia (104)
Cardiac failure chronic (103)
Neoplasm (101)
Chronic obstructive pulmonary disease (89)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)